Unicycive Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
/ 
Frequently asked questions
To buy Unicycive Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Unicycive Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Unicycive Therapeutics Inc. is UNCY:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Unicycive Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade Unicycive Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Unicycive Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Unicycive Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Unicycive Therapeutics Inc..